Regulus Therapeutics Inc
RGLS7.980USD
+4.610+136.80%
Close 04/30, 16:00（ET）Quotes delayed by 15 min
522.69MMarket Cap
LossP/E TTM
More Details of Regulus Therapeutics Inc Company
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Company Info
Company codeRGLS
Company nameRegulus Therapeutics Inc
IPO dateOct 04, 2012
Founded at2007
CEOMr. Joseph P. (Jay) Hagan
Number of employees34
Security typeOrdinary Share
Fiscal year-endOct 04
Address4224 Campus Point Court
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92121
Phone18582026300
Websitehttps://www.regulusrx.com/
Company codeRGLS
IPO dateOct 04, 2012
Founded at2007
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
978.39K
+75.85%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
45.48K
+686.54%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Director
Independent Director
39.06K
--
Mr. Preston S. Klassen, M.D.
Mr. Preston S. Klassen, M.D.
President, Head of Research & Development, Director
President, Head of Research & Development, Director
36.05K
--
Dr. David Baltimore, Ph.D.
Dr. David Baltimore, Ph.D.
Independent Director
Independent Director
22.17K
+766.31%
Ms. Pascale Witz
Ms. Pascale Witz
Independent Director
Independent Director
4.73K
--
Mr. Joseph P. (Jay) Hagan
Mr. Joseph P. (Jay) Hagan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Rekha Garg
Ms. Rekha Garg
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
978.39K
+75.85%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
45.48K
+686.54%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Director
Independent Director
39.06K
--
Mr. Preston S. Klassen, M.D.
Mr. Preston S. Klassen, M.D.
President, Head of Research & Development, Director
President, Head of Research & Development, Director
36.05K
--
Dr. David Baltimore, Ph.D.
Dr. David Baltimore, Ph.D.
Independent Director
Independent Director
22.17K
+766.31%
Revenue Breakdown
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Federated Hermes Global Investment Management Corp.
19.40%
New Enterprise Associates (NEA)
9.76%
Vivo Capital, LLC
7.55%
Octagon Capital Advisors LP
7.32%
The Vanguard Group, Inc.
5.99%
Other
49.98%
Shareholder Statistics
Shareholder
Proportion
Federated Hermes Global Investment Management Corp.
19.40%
New Enterprise Associates (NEA)
9.76%
Vivo Capital, LLC
7.55%
Octagon Capital Advisors LP
7.32%
The Vanguard Group, Inc.
5.99%
Other
49.98%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
32.76%
Hedge Fund
27.99%
Venture Capital
17.31%
Investment Advisor
7.47%
Individual Investor
2.18%
Research Firm
0.97%
Bank and Trust
0.11%
Pension Fund
0.08%
Other
11.13%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
137
56.09M
84.68%
-6.17M
2024Q4
137
55.74M
85.10%
-6.54M
2024Q3
128
58.95M
90.05%
-6.89M
2024Q2
113
63.43M
96.89%
+3.08M
2024Q1
85
60.55M
95.51%
+47.86M
2023Q4
70
12.67M
62.78%
-270.56K
2023Q3
77
12.73M
68.68%
-335.94K
2023Q2
80
12.00M
64.97%
-983.27K
2023Q1
89
9.82M
61.73%
-1.56M
2022Q4
92
9.90M
62.22%
-2.24M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Federated Hermes Global Investment Management Corp.
12.85M
19.4%
--
--
Dec 31, 2024
New Enterprise Associates (NEA)
6.47M
9.76%
--
--
Dec 31, 2024
Vivo Capital, LLC
5.00M
7.55%
--
--
Dec 31, 2024
Octagon Capital Advisors LP
4.85M
7.32%
+585.10K
+13.72%
Dec 31, 2024
The Vanguard Group, Inc.
3.97M
5.99%
-121.67K
-2.98%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.89M
5.88%
+146.29K
+3.90%
Dec 31, 2024
Point72 Asset Management, L.P.
895.13K
1.35%
+1.37K
+0.15%
Dec 31, 2024
Deep Track Capital LP
3.26M
4.93%
--
--
Dec 31, 2024
Millennium Management LLC
2.19M
3.31%
+900.74K
+69.75%
Dec 31, 2024
Adage Capital Management, L.P.
2.00M
3.02%
--
--
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Date
Type
Ratio
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1